Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06743649 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1-PF-06743649 or placebo | EXPERIMENTAL | Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3 |
| Cohort 2-PF-06743649 or placebo | EXPERIMENTAL | - |
| Cohort 3-PF-06743649 or placebo | EXPERIMENTAL | - |
| Cohort 4-PF-06743649 or placebo | EXPERIMENTAL | - |
| Cohort 5-PF-06743649 or placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-06743649 | DRUG | 40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days |
| Placebo | DRUG | Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG...
PF-06743649 is an investigational small molecule drug developed by Pfizer, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers, evaluating safety, toleration, pharmacokinetics, and pharmacodynamics after multiple oral doses. It is not approved for any indication and remains in early clinical development.
PF-06743649 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in the United States.
PF-06743649 is in Phase 1 clinical development. Its only recorded trial, NCT02151617, was a Phase 1 study that has been completed. The drug is investigational and has not been approved by the FDA for any indication.
PF-06743649 has been studied in one clinical trial, NCT02151617, titled a study in healthy people to evaluate safety, toleration, pharmacokinetics and pharmacodynamics of multiple oral doses of PF-06743649. The Phase 1 trial enrolled 40 healthy volunteers in the United States and is now completed, with no active trials ongoing.
The Phase 1 trial of PF-06743649, NCT02151617, was a randomized, double-blind, controlled study conducted in the United States. It enrolled 40 healthy adult volunteers of all sexes, aged 18 years and older, and assessed safety, toleration, pharmacokinetics, and pharmacodynamics following multiple oral doses of the drug.